Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pentoxyverine bromide
- Development stage
- Phase 2
- Lead developer
- Chengdu First Pharmaceutical
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Pentoxyverine bromide is a non-opioid antitussive small molecule being developed as an inhaled aerosol for the treatment of chronic obstructive pulmonary disease (COPD). It primarily functions as a sigma-1 receptor agonist and a muscarinic acetylcholine receptor antagonist. While traditionally used orally for cough suppression, the aerosolized formulation by Chengdu List Pharmaceutical aims to leverage its bronchodilatory and antitussive properties directly in the airways to manage symptoms in patients with mild to moderate stable COPD. Its mechanism involves the inhibition of the cough reflex and potentially bronchodilation through its muscarinic antagonist activity.
- Other names
- carbetapentane bromide
02
Targets
mAChR (Muscarinic acetylcholine receptors)SIGMAR1 (Sigma non-opioid intracellular receptor 1)
Beyond the preview
Go deeper on pentoxyverine bromide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pentoxyverine bromide.